Drug shortage
Dihydroergotamine Mesylate Injection · Padagis US LLC
FDA drug shortage · To Be Discontinued · updated Sep 16, 2024
Key facts
| Generic name | Dihydroergotamine Mesylate Injection |
|---|---|
| Company | Padagis US LLC |
| Presentation | Injection, 1 mg/1 mL (NDC 0574-0850-10) |
| Dosage form | Injection |
| Strength | 1 mg/1 mL |
| Status | To Be Discontinued |
| Therapeutic category | Neurology |
| Package NDCs | 0574-0850-10 |
| First posted | Sep 16, 2024 |
| Last updated | Sep 16, 2024 |
| Discontinued | Sep 16, 2024 |
At a glance
- 1–9 Package NDCs affected
- 1–9 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: